NCT04609098View on ClinicalTrials.gov

Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

December 2, 2020

Study Completion Date

December 23, 2020

Conditions
Malaria, Falciparum
Interventions
DRUG

Dihydroartemisinin/Piperaquine

Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.

DRUG

Tafenoquine 100mg [Arakoda]

Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.

Trial Locations (1)

Unknown

Malaria Research and Training Centre, Bamako

All Listed Sponsors
lead

London School of Hygiene and Tropical Medicine

OTHER

NCT04609098 - Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) | Biotech Hunter | Biotech Hunter